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Introduction > Human papillomavirus (HPV) is the main cause of cervical cancer. In France, since
March 2007, HPV vaccination has been recommended for girls aged 14, in addition to a catch-up
program for girls aged 15 to 23. In October 2012, the target population was changed to 11- to 14-
year-old girls. The main objective of the present study was to evaluate the impact of the
recommendation change on HPV vaccination coverage and compliance.
Methods > We conducted a descriptive study of the Échantillon Généraliste des Bénéficiaires (EGB),
which is a random 1/97 permanent sample from the French National Health Insurance Database.
We focused our analyses on girls aged 11 to 17 years who were covered by the main insurance
scheme (which covers 77% of the French population).
Results > We included 16,195 girls in this analysis. At the last update of the database (06/15/
2014), 42% of 17-year-old girls had been vaccinated, with more than 50% of them having been
vaccinated at age 14. Between January 2012 and June 2014, patients were reimbursed for a total
of 7698 doses of the HPV vaccine. During the first trimester of 2013, the number of vaccinated 11-
to 13-year-old girls increased, growing by more than 20-fold between the last trimester of 2012
(n = 8) and the last trimester of 2013 (n = 178). Less than 60% of the vaccinated patients received
3 injections.
Discussion > Implementation of the new recommendations was rapid but had only a slight impact
on vaccination coverage.
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Résumé
Impact de l'âge sur la couverture vaccinale anti-HPV en France en 2014 : une étude
réalisée à partir des données de l'échantillon généraliste des bénéficiaires (EGB)
Introduction > Le papillomavirus humain (HPV) est la principale cause de cancer du col. En France,
la vaccination anti-HPV est recommandée depuis mars 2007 chez les jeunes ﬁlles âgées de
14 ans, avec un programme de rattrapage des jeunes ﬁlles âgées de 15 à 23 ans. En octobre
2012, la population cible a été modiﬁée comprenant les jeunes ﬁlles de 11 à 14 ans. L'objectif de
cette étude est d'évaluer l'impact des modiﬁcations des recommandations sur la couverture
vaccinale anti-HPV et l'observance.
Méthodes > Nous avons mené une étude rétrospective à partir des données de l'EGB (échantillon
généraliste des bénéﬁciaires) qui correspond à 1/97 de la population présente dans la base de
l'Assurance maladie. Nous avons ciblé les jeunes ﬁlles de 11 à 17 ans couvertes par le Régime
Général (couvrant 77 % de la population française).
Résultats > L'analyse a concerné 16 195 ﬁlles. À la dernière mise à jour avant analyse, 42 % des
jeunes ﬁlles de 17 ans avaient été vaccinées, dont plus de 50 % à l'âge de 14 ans. Entre janvier
2012 et juin 2014, 7698 doses de vaccins ont été remboursées. Lors du 1er trimestre 2013, la part
des 11–13 ans vaccinées a augmenté, jusqu'à être multipliée par 20 entre le dernier trimestre
2012 et le dernier trimestre 2013. Moins de 60 % des patientes ont reçu les 3 doses recom-
mandées à l'époque.
Discussion > L'implémentation des nouvelles recommandations concernant l'âge a été rapide.
Toutefois, la couverture vaccinale anti-HPV est toujours basse.
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Human papillomavirus (HPV) is the main cause of cervical cancer
[1]. The high-risk subtypes HPV 16 and 18 are responsible for
70% of cervical cancer cases [2]. In France, in 2012, there were
3028 new cases of cervical cancer and 1102 deaths from the
disease [3]. HPV is also responsible for cervical intraepithelial
neoplasia (CIN), a precancerous lesion that can necessitate
surgical procedures and that requires close follow-up of patients
[2]. In several countries (Australia, Great Britain, and the United
States) with a national HPV vaccination program, we have
observed a decrease in HPV prevalence in the vaccinated popu-
lation [4–6]. In addition, HPV vaccination has been shown to
reduce CIN prevalence in vaccinated patients in Australian stud-
ies [7,8]. HPV vaccination has been recommended and its costs
covered by the French health authorities since March 2007 [9].
However, there is no national HPV vaccination program in
France. From March 2007 to September 2012, HPV vaccination
was recommended for girls aged 14, in addition to a catch-up
program for girls aged 15 to 23 who had become sexually active
within the previous year or who had not yet initiated sexual
activity [10]. Since October 2012, the target population has
changed from 14-year-old girls to 11- to 14-year-old girls
[11]. In early 2014, the French health authorities revised their
existing recommendations from a 3-dose schedule to a 2-dose
schedule [12,13]. The impact of the target age change on HPV
vaccination coverage and compliance is unknown.tome 102 > n811 > November 2015The main objective of this study was to evaluate the implemen-
tation of recommendations concerning target age and the
impact of these recommendations on HPV vaccination coverage
and compliance.Materials and methods
Data source
Data were extracted from the Échantillon Généraliste des
Bénéficiaires (EGB), which is a random 1/97 permanent sam-
ple from the French National Health Insurance Database [14].
This national database includes reimbursement within the
three main insurance schemes, which cover nearly 85% of
the French population. On June 15, 2014, the EGB covered
708,208 people, including both those who consume health
services and those who do not. The data in the EGB include
patient characteristics, all reimbursed medical costs, prescrip-
tions, administered laboratory tests, private hospital data,
partial public hospital data and vital status. The use of the
EGB is regulated, and the data are anonymous. We obtained
authorization to access the EGB database from the French
National Health Insurance system (CNAM, or Caisse Nationale
d'Assurance Maladie). The data were prospectively collected
beginning in 2005. No clinical investigation was conducted,
and no personal identifiers were included; therefore, no IRB
approval was sought for this study.89
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Figure 1
HPV vaccination coverage of girls aged 11 to 17 years at the last
database update (06/15/2014). a: vaccination rates; b: age at
the time of vaccination
D. Héquet, N. Pouget, J-P Estevez, M. Robain, R. Rouzier
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We restricted analysis to individuals insured by the main health
insurance scheme, covering 77% of the population, because
data on the two other schemes of the EGB were only available
after 2011. The patients had to be insured by the main health
insurance scheme at the date of analysis and since the begin-
ning of data collection to avoid loss of reimbursement informa-
tion. We focused our analysis on girls aged 11 to 17 years.
Indeed, girls younger than 11 are not administered HPV vacci-
nation in France, and girls older than 17 often change health
insurance schemes when they become students in secondary
education. For all of the girls in the selected population, we
obtained information concerning their month and year of birth.
For each vaccinated girl, the following information was avail-
able: the date of each vaccine injection (month and year), the
type of vaccine (Cervarix® or Gardasil®), and the number of
injections. In our study, we assumed that every dose registered
had been administered and that patients had been reimbursed
for all administered doses.
Statistical methods
All statistical analyses were performed using R software
(http://cran.r-project.org, The R Foundation for Statistical Com-
puting, Vienna, Austria, version 0.98.978, ©2009–2013 RStudio,
Inc.). We used classic descriptive statistical methods. The study
population was considered to be exhaustive and did not repre-
sent a sample; therefore, confidence intervals are not given with
the results. Comparisons of compliance between the different
periods were performed using Pearson's chi-square test.
Results
Number of covered vaccine doses
Between January 2012 and June 2014, patients were reimbursed
for a total of 7698 doses of the HPV vaccine. The Gardasil®
vaccine represented 84% of these doses (n = 7698). Analysis by
trimester showed an increase in covered doses from June to
December 2013, followed by a decrease in the number of both
Gardasil® and Cervarix® doses in 2014 compared with the rate
observed in 2012.
Coverage of the study population
We examined the vaccination rates (at least one vaccine dose
with reimbursement) as of June 15, 2014, the date that the
database was last updated. The vaccination rates were
described by age at the time of the last update (ﬁgure 1a).
Of the 16,195 girls aged 11 to 17, 18.2% (n = 2940) had been
vaccinated by the time of analysis. The majority of vaccinated
girls who were 15, 16 or 17 years old on June 15, 2014, had
received their first HPV vaccine injection at 14 years of age
(54%, n = 1208). The age at vaccination was lower for girls who
were younger at the time of analysis (ﬁgure 1b), demonstrating
implementation of the current recommendations.Evolution of the vaccination rates by age from
January 2012 to June 2014
The evolution of the vaccination rates by age is reported in
ﬁgure 2. Globally, we observed an increase in the vaccination
rate among 11- to 17-year-old girls (at least one vaccine dose
with reimbursement), from 5.4% in 2012 to 8.1% in 2013.
Moreover, the vaccination rate among 11- to 13-year-olds
increased by 10-fold between 2012 and 2013 (from 0.6% to
6.2%). In addition, when we performed analysis by quarter, we
observed that the number of vaccinated girls aged 11 to 13 years
increased, growing more than 20-fold between the last quartile
of 2012 (n = 8) and the last quartile of 2013 (n = 178). The
numbers of 14-year-old and 15- to 17-year-old girls who had
received a vaccination were globally stable, even though sea-
sonality was obvious. This finding suggests that moving the
target population from 14-year-old girls to 11- to 14-year-old
girls increased the coverage rate.
Evolution of HPV vaccination compliance by age
between January 2012 and June 2014
We studied the number of injections for which vaccinated patients
were reimbursed between January 2012 and June 2013. We did
not consider the period from July 2013 to June 2014. However,
certain patients did not have time to complete the vaccination
because it is recommended that the last dose be administered
6 months after the first dose, with an elasticity of one year. Amongtome 102 > n811 > November 2015
Figure 2
Evolution of vaccination coverage by age in 2012/2013. a:
vaccination rates by age in 2012/2013; b: number of first
injections by age
TABLE IA
HPV vaccination compliance depending on the age at first injection
Target age, n = 504 
n % 
1 dose 80 15.9 
2 doses 82 16.3 
3 doses 342 67.9 
TABLE IB
HPV vaccination compliance depending on the period of first injecti
January–June 2012, n = 375 July–December
n % n 
1 dose 56 14.9 86 
2 doses 49 13.1 73 
3 doses 270 72.0 267 
Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance
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3 injections, as recommended by the French health authorities
during this time period. Compliance with the vaccination scheme
was better for the target population (14-year-old girls) compared
with 15- to 17-year-old girls (P = 0.009), as presented in table Ia.
Of concern, we observed a decrease in compliance from January
2012 (72%) to June 2013 (56.1%, P = 0.0005). Table Ib reports the
evolution of compliance between January 2012 and June 2013.
Figure 3 shows the evolution of the number of doses covered by
insurance among vaccinated patients from 2012 to 2013 by age.
Discussion
This study analyzed HPV vaccination rates in a huge population
of French girls (16,195) ranging in age from 11 to 17 years old.
The data on the study population came from the EGB, which is a
random 1/97 permanent sample from the French National
Health Insurance Database, a national database that covered
708,208 people at the last update (06/15/2014). Data are
available on both patients who consume health services and
those who do not, which permitted us to evaluate vaccination
rates. Moreover, the database provides exhaustive data on
reimbursement for medicines and is a fantastic tool for epide-
miological analyses [15]. However, the EGB presents certain
limitations. First, we had access to reimbursement data, but
not administration data; consequently, we cannot be sure that
medicine delivered at the pharmacy was really administered to
the patient. Studies using this database are strongly controlled
to protect individuals; that is, certain data are considered to be
"sensitive'' and cannot be obtained. Second, in this particularCatch up age, n = 611
n % P
141 23.1
99 16.2
371 60.7 0.009
on (among 14- to 17-year-old girls)
 2012, n = 426 January–June 2013, n = 314
% n % P
20.2 79 25.2
17.1 59 18.8
62.7 176 56.1 0.0005
89
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Figure 3
Evolution of vaccine doses delivered, depending on the age at vaccination
D. Héquet, N. Pouget, J-P Estevez, M. Robain, R. Rouzier
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for patients over 17 who became secondary education students.
Therefore, we focused our study on patients aged 11 to 17 years.
Finally, because the primary objectives of the database are
reimbursement and protection of patient confidentiality, there
are few social or medical data on the patients. However, the EGB
currently remains the most useful tool to evaluate vaccination
rates and is therefore used by the national health authorities to
set up new recommendations [16].
In this study, we reported vaccination rates (at least one injec-
tion with reimbursement) of 33.7% among girls aged 16 years
and 21.5% among girls aged 15 years in June 2014. In 2011, the
vaccination rate for girls aged 15 was higher, reaching 26% [16].
Similar results were described in a French study published in
2014 concerning 1136 mothers of girls 14 to 16 years of age
[17]. Based on a self-administered questionnaire, the authors
describe that 31.7% of 14–16-year-old girls had started the
vaccination schedule. Based on ﬁgure 1b, we do not suspect
that better coverage of younger girls explains this decrease.
These rates are very low compared with those in other countries,
such as Australia (70%), Denmark (82%), Great Britain (80%)
and Canada (75%) [6,7,18,19].
In October 2012, the French authorities changed the recom-
mendations on HPV vaccination: the target population changed
from girls aged 14 years to girls aged 11 to 14 years. As early as
January 2013, we observed a large increase in vaccinated girls
aged 11 to 13 years. However, even if the new recommenda-
tions were rapidly implemented and had a positive impact,
vaccination coverage remains too low. We showed highernumbers of doses and patients vaccinated in 2013 after the
new recommendations of October 2012. However, this effect
was temporary because a decrease was observed in the first
trimester of 2014. An anticipated effect of the two-dose sched-
ule is suspected, but further studies are warranted.
We observed poor adherence to the vaccination protocol, with
only 59% of patients receiving 3 injections between January
2012 and June 2013. Better compliance was observed in the girls
of the target age compared with the catch-up population. In
2010, a study on HPV vaccination coverage in Paris found that
only 43% of vaccinated patients had received a complete vacci-
nation scheme, with 3 doses [20]. Moreover, vaccination cover-
age rate had decreased (11 to 16 points depending of age)
between 2009 and 2012 [17]. The better compliance observed
in the youngest girls is a clear benefit of lowering the target age
for HPV vaccination. A positive effect is also expected for the
two-dose schedule [12,13].
In France, there is no national vaccination program. However,
the last report from the health authorities introduced a project to
organize an extensive vaccination campaign at schools [16].
National HPV vaccination programs have been already set up in
several countries, including Australia, Denmark, Great Britain,
New Zealand, the United States (only certain states), Sweden,
Germany and Canada. This approach seems to be the most
effective for improving vaccination coverage. Therefore, vacci-
nation coverage in these countries is up to 82% [18]. The French
national health authorities' decision to establish a national
program is a consequence of both poor vaccination coverage
and the growing number of publications on HPV vaccinationtome 102 > n811 > November 2015
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in HPV prevalence were observed in 77% and 56% of vaccinated
patients, respectively [12,13]. Moreover, decreases in CIN prev-
alence were observed in vaccinated patients in Australia and
Canada [7,8,4].
Conclusion
This observational study conducted to evaluate a large French
population revealed a poor HPV vaccination coverage rate.
National health authorities often change recommendations to
improve vaccination rates. In fact, we observed very rapid
implementation of the new recommendations. However,References
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